| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C17H18FN3O3.2ClH.3H2O |
| Molecular Weight | 789.651 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.Cl.Cl.OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O.OC(=O)C5=CN(C6CC6)C7=CC(N8CCNCC8)=C(F)C=C7C5=O
InChI
InChIKey=SMFVXHJJUFAKBS-UHFFFAOYSA-N
InChI=1S/2C17H18FN3O3.2ClH.3H2O/c2*18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24;;;;;/h2*7-10,19H,1-6H2,(H,23,24);2*1H;3*1H2
Ciprofloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid) is the synthetic antimicrobial agent for oral or intravenous administration. Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents. The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination. Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid. In the United States, ciprofloxacin is pregnancy category C. This category includes drugs for which no adequate and well-controlled studies in human pregnancy exist, and for which animal studies have suggested the potential for harm to the fetus, but potential benefits may warrant use of the drug in pregnant women despite potential risks. Fluoroquinolones have been reported as present in a mother's milk and thus passed on to the nursing child. Oral and intravenous ciprofloxacin is approved by the FDA for use in children for only two indications due to the risk of permanent injury to the musculoskeletal system: Inhalational anthrax (postexposure) and Complicated urinary tract infections and pyelonephritis due to Escherichia coli.
CNS Activity
Originator
Approval Year
Cmax
AUC
T1/2
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Sourcing
Sample Use Guides
Skin and Skin Structure 500 -750 mg every 12 hours 7 to 14 days
Bone and Joint 500-750 mg every 12 hours 4 to 8 weeks
Complicated Intra-Abdominal 500 mg every 12 hours 7 to 14 days
Infectious Diarrhea 500 mg every 12 hours 5 to 7 days
Typhoid Fever 500 mg every 12 hours 10 days
Uncomplicated Gonorrhea 250 mg single dose single dose
Inhalational anthrax (pos-exposure) 500 mg every 12 hours 60 days
Plague 500–750 mg every 12 hours 14 days
Chronic Bacterial Prostatitis 500 mg every 12 hours 28 days
Lower Respiratory Tract 500 -750 mg every 12 hours 7 to 14 days
Urinary Tract 250-500 mg every 12 hours 7 to 14 days
Acute Uncomplicated Cystitis 250 mg every 12 hours 3 days
Acute Sinusitis 500 mg every 12 hours 10 days
Route of Administration:
Oral
Eight hospital isolates of methicillin-resistant and two standard strains of S. epidermidis (ATCC 12228, ATCC 35984) were cultured overnight in Tryptone Soy Broth supplemented with 0.5% glucose. The solution of tested compounds in TSB-glucose medium were mixed (1:1) with the bacterial inoculums (10^7 CFU/mL) in sterile 96-well polystyrene microtiter plates (Karell - Medlab, Italy) and incubated at 37 C for 24 h. Ciprofloxacin was used as the reference antimicrobial compound; its final concentration ranged from 0.125 to 8 mkg/ml.
ACTIVE MOIETY
SUBSTANCE RECORD
